Abstract:Objective To investigate the possibility of using melanoma antigen-1 (MAGE-1) peptide as a tumor vaccine to treat hepatocellular carcinoma ( HCC).Methods The expressions of MAGE-1 in 8 HCC cell lines and in liver cancer tissue from a patient were detected using RT-PCR. The type of human leucocyte antigen I (HLA I) of both 8 HCC cell lines and peripheral blood mononuclear cells of the patient was detected using a microcytotoxicity method to screen out target cell lines for the cytotoxicity assay. Peripheral blood mononuclear cells from the HCC patient pulsed with an MAGE-1 pepticle ( NYKCRFPEI) were used as antigen presenting cells. Autogenous peripheral blood mononuclear cells were stimulated with antigen presenting cells every 7 days for 4 times to elicit cytotoxic T lymphocytes. The phenotype of effector cells was analyzed using flow cytometry. The cytotoxicity of effector cells was detected with a lactate dehydrogenase releasing assay.Results The expressions of both MAGE-1 and HLA-A24 were detected in BEL7405 cell line which were used as the positive target cell line in the cytotoxicity assay. The expression of MAGE-1 alone was detected in HLE, BEL7402, BEL7404, QGY7703 and SMMC7721 cell lines, and the expression of neither MAGE-1 nor HLA-A24 was shown in QGY 7701 and HpG2 cell lines. The last 7 cell lines could be used as negative target cell lines in the cytotoxicity assay. Peripheral blood mononuclear cells expanded 32 folds during 28-day culture. The ratio of CD3(+) T cells increased by 16% (from 54% to 70%), and the ratio of CD8(+) T cells increased by 20% (from 36% to 56%) during 28-day culture. When the ratio of effector cells to target cells was 10: 1, effector cells exhibited 62.5% cytotoxicity against autogenous lymphoblasts pulsed with the peptide (NYKCRFPEI) of MAGE-1 antigen, 40.25% cytotoxicity against BEL7405 cells, compared with 17.88% cytolysis observed against autogenous lymphoblasts, 19.55% against HLE cells, and 1.6% against QGY7701 cells. When the ratio of effector cells to target cells was 3. 3:1, the cytotoxicity of effector cells against the peptide pulsed autogenous lymphoblasts was 53.6%, which was much higher against autogenous lymphoblasts, HLE cells and QGY7701 cells at 15.6%, 13% and 1%, respectively.Conclusion The results demonstrate that cytotoxic T lymphocytes with the ability to specifically lyse target cells expressing both MAGE-1 and HLA-A24 could be successfully induced by the MAGE-1 peptide NYKCRFPEI in vitro. This indicates that a good result might be anticipated if this peptide is used as a tumor vaccine to treat HLA-A24 HCC patients.

Heat Shock Protein 70 / MAGE-1 Tumor Vaccine Can Enhance the Potency of MAGE-1–specific Cellular Immune Responses in Vivo

Heat Shock Protein 70/MAGE-3 Fusion Protein Vaccine Can Enhance Cellular and Humoral Immune Responses to MAGE-3 in Vivo.

Fusion of Hsp70 to Mage-a1 enhances the potency of vaccine-specific immune responses

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

Gas‑filled Ultrasound Microbubbles Enhance the Immunoactivity of the HSP70‑MAGEA1 Fusion Protein Against MAGEA1‑expressing Tumours

Antitumor therapeutic effect induced by intestine- carcinoma cells vaccine expressing membrane- bound heat shock protein 70

Recent Advances in Heat Shock Protein-Based Cancer Vaccines

Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene.

Heat Shock Fusion Protein Induces Both Specific And Nonspecific Anti-Tumor Immunity

The Anti-Tumor Immune Response Induced by A Combination of Mage-3/Mage-N-Derived Peptides

Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy.

Modulatory Effects of Tumor-Derived Heat Shock Protein in DNA Vaccination Against Nasopharyngeal Carcinoma

Construction,expression and purification of a fusion gene of MAGE-n peptide with human heat shock protein 70

Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.

Construction and immunologic competence of MAGE-1 gene vaccine

Efficacy of MAGE-A4 Long Peptide As a Universal Immunoprevention Cancer Vaccine

[Study of the Cytotoxity Against Human Hepatocellular Carcinoma Cells Induced by the MAGE-1 Gene Modified Dendritic Cells].

Fusion Proteins of Hsp70 with Tumor-Associated Antigen Acting As A Potent Tumor Vaccine and the C-Terminal Peptide-Binding Domain of Hsp70 Being Essential in Inducing Antigen-Independent Anti-Tumor Response in Vivo

Induction of Cytotoxic T Lymphocytes from the Peripheral Blood of A Hepatocellular Carcinoma Patient Using Melanoma Antigen-1 (Mage-1) Peptide

A Cpg Oligodeoxynucleotide Potentiates the Anti-Tumor Effect of Hsp65-Her2 Fusion Protein Against Her2 Positive B16 Melanoma in Mice

Hsp70-Like Protein 1 Fusion Protein Enhances Induction Of Carcinoembryonic Antigen-Specific Cd8(+) Ctl Response By Dendritic Cell Vaccine